Hits: 1888

The Myelofibrosis Risk Assessment Tool grew out of the work of the MS3T, the MPN Stem Cell Transplantation Timing Taskforce 

For MF patients with high risk or progressing myelofibrosis, the only cure is a stem cell transplant.  The timing of the SCT is critical and too often MF patients delayed the procedure until the onset of blast phase of progression to Acute Myeloid Leukemia where the  outcomes were unfavorable.   Internationally renowned hematologists, transplanters, pathologists, teamed up with MPN patient advocates in Taskforce focused on this issue.

The conclusion: A simple, free, graphically striking on-line tool that incorporated current findings on myelofibrosis assessment could help reduce the toll resulting from delay of stem cell transplant.

The MS3T  reviewed the clinically validated DIPSS and DIPSS+  scales that measured myelofibrosis risk levels and consulted on the construction of the Stem Cell Transplant Timing Tool (SSTT, http://www.mpntransplant.com/)

The same scoring scales and risk assessment that applied to SCT timing is applicable to prognostic application in myelofibrosis as an aid to determining levels of treatment, from Watch & Wait or low level intervention in low risk MF to SCT or entry to clinical trial for higher risk levels. Adapting the SCT tool to the general MF population was a natural extension of the Taskforce’s work.

The addition of mutational burden added an extra dimension to the tool. The new tool, renamed MAGIC (Myelofibrosis Assessment Graphic Internet Calculator) simply lists and totals mutations. The mutation analysis section is integrally linked to   “Notes on MPN Mutations,”here and in the MPN Quarterly Journal  The Notes provide more detail on the most common MPN mutations and a general background on the MPN mutational landscape..

The MPN Research Foundation sponsored both the SSTT and the M/RAT as part of its myelofibrosis and SCT education and patient support programming.

The MPN Research Foundation launch announcement to media is here.

 


 

Members, MS3T

 


Hematologists

Dr. Claire Harrison

Professor and Clinical Director, Guy’s and St. Thomas’ Hospital, London

Dr. Ruben Mesa

Director, Mays Cancer Center of UT Health San Antonio MD Anderson Cancer Center

Dr. Richard T. Silver

Professor of Medicine, Weill-Cornell 

Richard T Silver MD Myeloproliferative Neoplasms Center

Dr. Srdan Verstovsek

Department of Leukemia, UT MD Anderson Cancer Center, Houston

Transplant specialists

Dr. Koen Van Besien

Director, SCT program, Weill-Cornell

Dr. Nicolaus Kroeger

Medical Director, SCT, University Hospital, Hamburg

Dr. Jeanne Palmer

Medical Director, BMT, Mayo Clinic, Phoenix

Dr. Uday Popat

Professor Dept of SCT, MD Anderson


Hematopathologist

Dr. Attilio Orazi

Professor of Pathology, Director of Hematopathology, Weill-Cornell


Adjunct Advisor

Dr. Wael Saber

Scientific Director, CIBMTR, Associate Professor

Medical College of Wisconsin


MPN SCT Patients

Chris Harper

Beatrice Larroque

Martin Prager


MPN Patient Advocates 

Ann Brazeau

MPN Advocacy and Education, CEO

Ann Haehn

President and Founder, Genny’s Hope Foundation 

Barbara Van Husen

CEO, MPN Research Foundation

Michelle Woerhle

Director, MPN Research Foundation


Project Director

Zhenya Senyak

Editor & Publisher, MPN Quarterly Journal/MPNforum

 


Sponsor:

The MPN Research Foundation

Special thanks to the MS3t Taskforce and to Ed Bartholemy, Diane Blackstock, Zeta Charania, John Crispino, David Denny, Brandon Goetz, Jacob Grinfeld, Claire Harrison, Ruben Mesa, Pam Murphy, Jerry Spivak and William Vainchenker.  Dedicated to the memory of Robert Rosen.